Insomnia
Insomnia is a common sleep disorder, affecting up to one third of the population. People with insomnia have trouble falling asleep, staying asleep, or both. These symptoms can last just a short time, such as several days, or continue long term.
There are a number of factors that contribute to insomnia, including stress, anxiety, a reaction to medication, certain medical disorders, excess stimulation and intake of drugs or alcohol.
Without enough sleep you may not feel refreshed when you wake up and can continue to feel tired during the day. This can result in difficulty concentrating, memory lapses and irritability.
If you only experience insomnia occasionally, it is unlikely to cause harm as the body can be revitalised by a few hours of extra sleep. However, long-term or frequent bouts of insomnia can have a negative effect on your health.
If you are concerned that you may be experiencing insomnia, it is important to speak with a healthcare professional.
ReDormin® (Ze91019) has been shown to assist in the relief of sleeplessness and insomnia.1-4 ReDormin contains standardised whole plant extracts of Valerian (Valeriana officinalis) and Hops (Humulus lupulus), in a combination that has been demonstrated, in clinical trials, to improve sleep quality.
Clinical trials have shown that ReDormin can significantly improve sleep:
- Decreasing the time taken to get to sleep (sleep latency)1,3
- Improving sleep quality, so that you wake less during the night and rise feeling more refreshed2
Situations that may benefit from ReDormin include:
- Difficulty getting to sleep
- Difficulty staying asleep i.e. waking during the night
- Trying to regulate sleep patterns e.g. shift workers, jet lag, chronic sleep disturbance
- Wanting to improve the quality of sleep, leading to feeling more refreshed the following day
Results from large-scale clinical trials suggest that ReDormin improves sleep quality and relieves insomnia. This is supported by the millions of doses purchased worldwide every year. In fact, 300 million doses of ReDormin have been sold worldwide since its launch in 1996. ReDormin has been shown to be very well tolerated, with no known risk of dependency.
ReDormin tablets contain a unique formulation (Ze 91019), made up of specific extracts of Valerian (Valeriana officinalis)and Hops (Humulus lupulus). ReDormin has been clinically proven, it is the exact product that has been used in numerous clinical trials. This is very important for natural medicines as there can be great variance between products, even if they appear to use the same active ingredients, due to the part of the plant that is used, as well as the growing, harvesting and production conditions & methods. The outcomes of clinical studies for natural medicines should therefore only apply to the exact product that has been tested. As a result, other products containing extracts of Valerian and Hops may not deliver the same results that ReDormin has demonstrated in the research.
Adults and adolescents 12 years and over: 2 tablets 1 hour before bed
While some people may notice an immediate improvement, it is likely to take several weeks to see the full benefits, and 1 month of continued treatment is usually recommended.
Always read the label. Use only as directed. If symptoms persist, it is important to speak with a healthcare professional.
ReDormin is clinically proven, it is the exact product that has been used in numerous clinical trials. This is very important for natural medicines as there can be great variance between products, even if they appear to use the same active ingredients, due to the part of the plant that is used, growing methods, harvesting processes and manufacturing methods. The outcomes of clinical studies for natural medicines may therefore only apply to the exact product that has been tested. As a result, other products containing extracts of Valerian and Hops may not deliver the same results that ReDormin has demonstrated in the research.
There is no evidence for any concern when using ReDormin in pregnancy and lactation, however, there are also no clinical studies that have been conducted with ReDormin in women who are pregnant or breastfeeding. As a result, ReDormin tablets should only be taken during this time under the advice and supervision of a healthcare professional.
Where appropriate, ReDormin can be prescribed for adolescents 12 years and older. If you have specific questions or concerns, it is important to speak with a healthcare professional.
ReDormin is very well tolerated and highly unlikely to cause side effects. Very occasionally, individuals may experience a skin reaction after taking ReDormin, resulting from sensitivity to the ingredients, which will resolve after ceasing the treatment. It is important to speak with a healthcare professional if you are concerned about possible side effects.
There are no known interactions between ReDormin tablets and other medications, however, caution is advised if you are currently taking sedative medication. If you are concerned about possible interactions, it is important to discuss this with your healthcare professional.
It is recommended to stop ReDormin 1 week prior to surgery. However, it is important to discuss this with your healthcare professional, including your anaesthetist and surgeon.
Yes, ReDormin is gluten free.
No, ReDormin does not contain lactose.
ReDormin tablets taken according to the recommended dose do not affect the ability to drive vehicles or operate machinery. However, taking ReDormin tablets immediately before driving a car or operating hazardous machinery is not recommended. The effect of ReDormin tablets may also be elevated by the consumption of alcohol.
ReDormin is available from naturopaths, selected health food stores and pharmacies. If you go to the Where to buy button above and follow the instructions, you will be able to find a list of practitioners, health food stores and pharmacies in your area who either stock ReDormin or will know how to order ReDormin. Even if your local pharmacy is not on the list, they will be able to order it in for you.
References: 1. Koetter U et al Phytother Res 2007; 21(9):847-851 2. Schmitz M and Jackel M Wien Med Wochenschr 1998; 148 (13):291-8 3. Füssel A et al Eur J Med Res 2000; 5:385-390 4. Lataster MJ and Brattström AJ Notabene Medici 1996; 6:182-5
Some of this research was conducted using funding provided by Max Zeller Soehne AG.
